Chance of reimbursement for ADD-ON therapies in Poland and in the world - review of the reimbursement recommendations.

Introduction: Oncology drugs combined with standard therapies (so-called add-on therapies, e.g. bevacizumab, palbociclib) often receive negative recommendations regarding the legitimacy of public financing, issued by government agencies responsible for their assessment, i.